At a Glance
Divi’s Laboratories has once again played the “API King” card with Q1 FY26 results. Revenue ₹2,529 Cr (+13.8% YoY) and PAT ₹545 Cr (+26.7% YoY) scream profitability. But the stock tanked 4% because Mr. Market hates high P/Es (70x) unless you’re wearing an AI badge. Margins are a juicy 30%, debt is negligible, and they’re still the favourite supplier to 12 of the top 20 Big Pharma giants. Yet, with domestic sales sluggish and valuations bloated, this stock might need a detox cycle.
Introduction
When it comes to APIs and custom synthesis, Divi’s is that nerd in class who tops every exam but still gets bullied for being too expensive. Based in Hyderabad and Vishakhapatnam, the company sells to 100+ countries and supplies carotenoids to everyone from supplement bros to feed manufacturers. It’s debt-free, has a cult following in pharma, and a 40%+ dividend payout.
But, like a protein shake that costs ₹1,200, the stock is premium – trading at 11x book and 70x earnings. So, while results impress, investors keep asking: “Is it worth the hype?”
Business Model (WTF Do They Even Do?)
- Generic APIs: 30 bulk APIs produced at scale; global exports.
- Custom Synthesis: Tie-ups with top pharma giants for exclusive molecule development.
- Nutraceuticals: Carotenoids and other active ingredients, global distribution.
- Clients: 12 of top 20 Big Pharma are long-term partners.
💬 Mini Roast: Divi’s makes the stuff that goes into the medicines you overpay for – and then overcharges you for the stock too.
Financials Overview
Q1 FY26
- Revenue: ₹2,529 Cr (+13.8% YoY)
- Operating Profit: ₹729 Cr (OPM 30%)
- PAT: ₹545 Cr (+26.7% YoY)
- EPS: ₹20.5
FY25 (Full Year)
- Revenue: ₹9,360 Cr
- PAT: ₹2,191 Cr
- ROE: 15.4% | ROCE: 20.4%
💬 Commentary: Margins hold steady at ~30%, growth
